Multiplexed DeNAno Protein Assay and Quantitation: Sequencing Based Proteomics

多重 DeNAno 蛋白质测定和定量:基于测序的蛋白质组学

基本信息

  • 批准号:
    8855369
  • 负责人:
  • 金额:
    $ 22.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-01-01 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Proteomics studies have the power to deliver pivotal new insight into cancer cells, biomarkers, and host responses. Unlike genomics, however, the field of proteomics has been constrained by a lack of simple and affordable analytical tools. Massively multiplex proteomic analysis methods remain expensive, cumbersome, and specialized. Here we propose the development of a novel assay termed MuDPAQ to occupy the niche for high throughput, highly multiplexed protein or biomarker assays that is currently poorly served with existing technologies. There is a growing need for assays of this type as tissue banks become more extensive, patterns of markers rather than single markers become validated, and as pharmacologic responses to therapy become more utilized. By reverse translating a protein detection event into a DNA signal, the MuDPAQ assay leverages the power and commoditization of next generation sequencing to enable massively parallel analyses that can be cheaply outsourced to any academic or commercial facility. The core of the technology is our "DeNAno" DNA nanoparticle, a novel biomolecular affinity reagent that replaces single or bi-valent affinity with hyper-avidity. DeNAno particles are produced by rolling circle replication of circular oligonucleotide templates. We have previously shown that when random templates are used to produce highly diverse libraries, particles that bind specifically to antibody coated beads can be easily recovered by biopanning. These particles, composed of concatameric repeats, bind to the cognate antibody coated bead through highly avid but individually low affinity interactions and can thus be competitively displaced by the appropriate antigen. DeNAno particles released from the beads can be sequenced, and the count frequency of the unique sequence of a given DeNAno particle translated into the quantity of its competitive analyte. When coupled with sequencing library tagging, this technology will enable high throughput analysis of multiple, multiplexed samples at a cost significantly below current technology and with no additional instrumentation required. For this Phase I proof-of-concept study, our aims will be to 1) select and validate masking DeNAno particles for each of ten mAb coated beads from a Luminex panel of cancer relevant biomarkers, and 2) demonstrate multiplexed analysis of all ten analytes. Successful completion of this study will validate the core concept behind MuDPAQ and lead to development of expanded panels of MuDPAQ reagents as well as further optimization of the assay performance. The long term goal of this proposal is to develop a catalog of MuDPAQ reagents that can be sold directly to researchers or licensed to sequencing companies or reagent manufacturers.
 描述(由申请人提供):蛋白质组学研究有能力提供对癌细胞、生物标记物和宿主反应的关键新见解。然而,与基因组学不同,蛋白质组学领域一直受到缺乏简单和负担得起的分析工具的限制。大规模多重蛋白质组分析方法仍然昂贵、繁琐和专业化。在这里,我们建议开发一种名为MuDPAQ的新分析方法,以占据高通量、高度多元化的蛋白质或生物标记物分析的利基市场,目前现有技术服务不足。随着组织库变得更加广泛,标志物而不是单一标志物的模式得到验证,以及对治疗的药理学反应变得更加有用,对这种类型的分析的需求越来越大。通过将蛋白质检测事件反向转换为DNA信号,MuDPAQ分析利用下一代测序的能力和商品化,实现大规模并行分析,这些分析可以廉价地外包给任何学术或商业机构。这项技术的核心是我们的“DeNAno”DNA纳米颗粒,这是一种新型的生物分子亲和剂,它用超亲和性取代了单价或双价亲和力。DeNAno颗粒是通过滚环复制环状寡核苷酸模板而产生的。我们之前已经证明,当随机模板被用来产生高度多样化的文库时,专门结合到抗体包被珠上的颗粒 可以通过生物扫描很容易地恢复。这些颗粒由串联重复序列组成,通过高度亲和力但个别低亲和力的相互作用与同源抗体包被珠结合,因此可以竞争地被适当的抗原取代。可以对从珠子中释放的DeNAno颗粒进行测序,并将给定的DeNAno颗粒的唯一序列的计数频率转化为其竞争分析物的数量。当与测序库标签相结合时,这项技术将能够以远低于当前技术的成本实现对多个多路复用样本的高通量分析,并且不需要额外的仪器。对于这项第一阶段的概念验证研究,我们的目标是:1)从Luminex癌症相关生物标志物小组中为10个单抗包裹的珠子中的每一个选择和验证掩蔽DeNAno颗粒,以及2)展示对所有10个分析物的多重分析。这项研究的成功完成将验证MuDPAQ背后的核心概念,并导致MuDPAQ试剂扩展小组的开发以及分析性能的进一步优化。这项提议的长期目标是开发一份MuDPAQ试剂目录,这些试剂可以直接出售给研究人员,或者许可给测序公司或试剂制造商。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BRADLEY T MESSMER其他文献

BRADLEY T MESSMER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BRADLEY T MESSMER', 18)}}的其他基金

Personalized precision dosing of anti-TNF biologic therapies
抗 TNF 生物疗法的个性化精确剂量
  • 批准号:
    9888300
  • 财政年份:
    2018
  • 资助金额:
    $ 22.5万
  • 项目类别:
Personalized precision dosing of biologic therapies in oncology
肿瘤学生物疗法的个性化精确剂量
  • 批准号:
    9984616
  • 财政年份:
    2017
  • 资助金额:
    $ 22.5万
  • 项目类别:
Novel Materials for Viral Purification
用于病毒纯化的新型材料
  • 批准号:
    9408588
  • 财政年份:
    2017
  • 资助金额:
    $ 22.5万
  • 项目类别:
Activin A antagonist for treatment of cancer-associated cachexia
激活素 A 拮抗剂用于治疗癌症相关恶病质
  • 批准号:
    9046615
  • 财政年份:
    2015
  • 资助金额:
    $ 22.5万
  • 项目类别:
Cleavage Coupled Lateral Flow Immunoassay for Rapid Endotoxin Testing
用于快速内毒素检测的裂解偶联侧向层析免疫分析
  • 批准号:
    8905383
  • 财政年份:
    2015
  • 资助金额:
    $ 22.5万
  • 项目类别:
Lateral Flow Immunoassay for Therapeutic Monoclonal Antibody Quality Assurance
用于治疗性单克隆抗体质量保证的侧流免疫分析
  • 批准号:
    8648070
  • 财政年份:
    2014
  • 资助金额:
    $ 22.5万
  • 项目类别:
HMGB1-Derived Peptides As Vaccine Adjuvants
HMGB1 衍生肽作为疫苗佐剂
  • 批准号:
    8435590
  • 财政年份:
    2012
  • 资助金额:
    $ 22.5万
  • 项目类别:
Molecular Evolution of Multifunctional DNA Nanoparticles
多功能DNA纳米颗粒的分子进化
  • 批准号:
    8293019
  • 财政年份:
    2011
  • 资助金额:
    $ 22.5万
  • 项目类别:
Molecular Evolution of Multifunctional DNA Nanoparticles
多功能DNA纳米颗粒的分子进化
  • 批准号:
    8472338
  • 财政年份:
    2011
  • 资助金额:
    $ 22.5万
  • 项目类别:
Molecular Evolution of Multifunctional DNA Nanoparticles
多功能DNA纳米颗粒的分子进化
  • 批准号:
    8035223
  • 财政年份:
    2011
  • 资助金额:
    $ 22.5万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 22.5万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 22.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了